MARKET

MNPR

MNPR

Monopar Therapeutics Inc
NASDAQ
74.61
-2.45
-3.17%
After Hours: 74.61 0 0.00% 17:59 12/12 EST
OPEN
76.51
PREV CLOSE
77.05
HIGH
76.90
LOW
73.63
VOLUME
248.66K
TURNOVER
--
52 WEEK HIGH
105.00
52 WEEK LOW
21.00
MARKET CAP
498.55M
P/E (TTM)
-21.7052
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at MNPR last week (1201-1205)?
Weekly Report · 6d ago
Weekly Report: what happened at MNPR last week (1124-1128)?
Weekly Report · 12/01 10:32
Weekly Report: what happened at MNPR last week (1117-1121)?
Weekly Report · 11/24 10:37
Optimistic Buy Rating for Monopar Therapeutics Inc: Promising ALXN1840 Data and Strong Financial Position
TipRanks · 11/18 18:45
Weekly Report: what happened at MNPR last week (1110-1114)?
Weekly Report · 11/17 10:38
Oppenheimer Sticks to Its Buy Rating for Monopar Therapeutics Inc (MNPR)
TipRanks · 11/14 12:55
MONOPAR THERAPEUTICS INC <MNPR.O>: RAYMOND JAMES CUTS TO OUTPERFORM FROM STRONG BUY; CUTS TARGET PRICE TO $123 FROM $142
Reuters · 11/14 12:22
This Home Depot Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Benzinga · 11/14 12:10
More
About MNPR
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.

Webull offers Monopar Therapeutics Inc stock information, including NASDAQ: MNPR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MNPR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MNPR stock methods without spending real money on the virtual paper trading platform.